
David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.
Alexander T. Pearson, MD, PhD, discusses how AI can be used for oncologic drug discovery and development.
Alexander T. Pearson, MD, PhD, explains how AI is being used for cancer drug discovery and development. He notes that the technology is able to quickly process vast amounts of information to identify compounds that could potentially be effective against cancer. Previous studies have shown that AI models can reduce the time it takes to develop a molecule suitable for study in a clinical trial from years down to months or even days, Pearson concludes.
